ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTMX vs PHAT // EV/EBITDA & P/E VALUATION

CytomX Therapeutics Inc. (NASDAQ) VS. Phathom Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: CTMX 3 — PHAT 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTMX VS. PHAT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTMX PHAT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 87.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -20.50% -35.00% +14.50 CTMX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -15.19% — — TIE /fcf-yield <GO>
Operating Margin -29.30% -60.00% +30.70 CTMX /operating-margins <GO>
Net Profit Margin -22.80% -0.10% -22.70 PHAT /net-margins <GO>
Revenue Growth (YoY) -44.80% 180.00% -224.80 PHAT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 4/9 -3.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.7 33.5 +9.20 CTMX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $499.0M $503.2M -$4.2M PHAT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTMX REV PHAT REV CTMX GROSS % PHAT GROSS % CTMX FCF PHAT FCF
FY 2025 $76.2M $175.1M — 87.1% -$75.8M -$167.0M
FY 2024 $138.1M $55.3M — 85.6% -$86.5M -$266.9M
FY 2023 $101.2M $682.0K — — -$56.0M -$137.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTMX // BETA —
PHAT // BETA —